ImmuniMed
Our goal - Mastery of
C. Difficile
Microbiome Immunotherapy to cure, prevent recurrance and stop C. Diff before it starts.
Ending the C. difficile Crisis: Prevention as the Ultimate Cure
Introducing CDiffControl: The world's first preventive treatment for C. difficile infection
The C. difficile Crisis
Clostridioides difficile infection (CDI) represents one of healthcare's most persistent and dangerous threats. This pathogen epitomizes a critical truth echoed since Hippocrates' era: "All disease begins in the gut."
CDI arises when antibiotics disrupt the delicate balance of the gut microbiome—a condition called dysbiosis—leaving patients vulnerable to relentless infections.
While many have pursued CDI as a stepping stone to broader microbiome therapies, we at ImmuniMed have chosen a different path: mastery.
The Devastating Impact of C. difficile
In severe cases, especially among the elderly or those with weakened immune systems, death rates reach 15-30% within 30 days of diagnosis.
The Vicious Cycle of Recurrence
Initial Infection
CDI diagnosis and initial antibiotic treatment. The cycle begins with the first infection, often acquired in healthcare settings or following antibiotic use.
First Recurrence
20-30% of patients relapse after initial treatment. Antibiotics disrupt the gut microbiome, making it vulnerable to reinfection by C. difficile spores.
Multiple Episodes
Recurrence rates jump to over 60% after multiple episodes. Each recurrence further damages the gut microbiome, creating a self-perpetuating cycle of infection.
Aggressive strains (like BI/NAP1/027) cause 20-30% of outbreaks, leading to higher death rates and treatment resistance.
Why Current Treatments Fall Short
CDI is not merely a gateway—it's a crisis. Current treatments fail to address its vicious cycle: antibiotics meant to cure often seed recurrence by sparing resilient C. difficile spores. Patients endure months of relapse, while clinicians face a shrinking arsenal against a CDC-designated "urgent threat".
Standard antibiotics (e.g., vancomycin) still carry a ~30% chance of the infection coming back. These treatments further damage the gut microbiome – a key factor in CDI.
With 1 in 11 seniors dying of CDI within a month of diagnosis, innovative therapies that restore gut health are critically needed to stop this epidemic or better still, CDiffControl, to prevent infection altogether.
Our Solution: A Comprehensive Approach
At ImmuniMed, we've dedicated ourselves to becoming the authority in CDI innovation—combining precision science with actionable solutions.
While others chase speculative microbiome applications, we deliver immediate impact where it's needed most. Our approach addresses CDI at every stage: curing active infections, protecting against recurrence, and most importantly—preventing infection before it starts.
Our Triple Defense: Cure, Protect, Prevent
Cure (CDiff FYX)
Ending active infections with unprecedented efficacy
Efficacy, Zero Compromise: Midway through Phase 2 trials, CDiff FYX has achieved a 94% cure rate—surpassing existing therapies—by delivering oral antibodies that neutralize toxins and eradicate active infections.
- Unlike antibiotics, our treatment leaves beneficial gut flora intact, addressing dysbiosis at its root
- With approval, CDiff FYX is poised to redefine frontline treatment
Protect (CDRIP)
Breaking the relapse cycle
Breaking the Relapse Cycle: C. difficile spores evade conventional antibiotics, lurking to reignite infection. CDRIP targets these spores directly, deploying antibodies to prevent germination.
- Prevents recurrence after initial treatment
- Addresses the core weakness of conventional antibiotics
Prevent (CDiffControl)
The world's first preventive treatment
Prevention as the Ultimate Cure: CDiffControl represents a paradigm shift—the first and only preventive therapy for high-risk patients, stopping CDI before it starts.
- For post-antibiotic or hospitalized individuals
- A paradigm shift from reactive care to true immunity
- Proactively protects the most vulnerable populations
Why CDiffControl Changes Everything
While others focus on treating infections, we're pioneering true prevention—the ultimate solution to the C. difficile crisis.
Proactive Protection
CDiffControl provides immunity before infection occurs, protecting vulnerable patients during high-risk periods
Break the Cycle
By preventing initial infection, we stop the vicious recurrence cycle before it starts
Cost Effective
Prevention dramatically reduces healthcare costs associated with CDI treatment and hospital stays
Join Us in Transforming CDI Care
At ImmuniMed, we don't just treat disease—we aim to erase it. By dominating the CDI landscape with CDiffControl, we're not claiming a niche; we're restoring dignity to patients and power to clinicians.
The gut may be where disease begins, but with your trust, it's where CDI's reign ends.